Valuation dashboard for Sarepta Therapeutics, Inc. (SRPT) with P/E N/A, P/B 1.30, EV/EBITDA -171.8 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.
Analysis Summary
Sarepta Therapeutics, Inc. reported revenue of $2.20B in the most recent fiscal year, growing at a 5-year CAGR of 32.4%.
Trailing-twelve-month margins: gross margin 58.6%, operating margin -7.3%, net margin -6.9%.
At $18.99 (closing price, November 4, 2026), SRPT has negative trailing earnings (P/E not meaningful) and an ROE of -9.96%. Market capitalisation stands at $2.0B.
Balance sheet quality for SRPT: debt-to-equity ratio of 0.68, current ratio of 4.42 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.30 |
| EV / EBITDA | -171.8 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $2.0B | 1.30 | -10.0% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $21.6B | 8.14 | 5.98 | 159.7% |
| IONS | Ionis Pharmaceuticals, Inc. | $6.7B | 15.41 | -110.8% | |
| PTCT | PTC Therapeutics, Inc. | $5.8B | 57.1% | ||
| DYN | Dyne Therapeutics, Inc. | $3.5B | 4.19 | -64.3% |
Price
| Price | $18.99 (closing price, November 4, 2026) |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -9.96% |
| Return on Invested Capital | -5.33% |
| Return on Assets | -4.29% |
| Gross Margin | 58.56% |
| Operating Margin | -7.26% |
| Net Margin | -6.93% |
Related companies: ALNY · IONS · PTCT · DYN
Explore sector: Healthcare · Biotechnology
More sections of SRPT: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks